WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |

Search International and National Patent Collections
World Intellectual Property Organization
Machine translation
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2005/068504    International Application No.:    PCT/JP2005/000567
Publication Date: 28.07.2005 International Filing Date: 19.01.2005
A61K 38/00 (2006.01), A61K 39/395 (2006.01), A61K 45/00 (2006.01), A61P 29/00 (2006.01), C07K 16/28 (2006.01), C12N 15/09 (2006.01), C12Q 1/02 (2006.01), G01N 33/15 (2006.01), G01N 33/50 (2006.01)
Applicants: MEDICAL AND BIOLOGICAL LABORATORIES CO., LTD. [JP/JP]; Sumitomo-shoji Marunouchi Bldg. 5F 5-10, Marunouchi 3-chome Naka-ku, Nagoya-shi Aichi 4600002 (JP) (For All Designated States Except US).
OKABE, Ayako [JP/JP]; (JP) (For US Only).
TOJI, Shingo [JP/JP]; (JP) (For US Only).
KISHI, Yoshiro [JP/JP]; (JP) (For US Only).
YAHARA, Ichiro [JP/JP]; (JP) (For US Only)
Inventors: OKABE, Ayako; (JP).
TOJI, Shingo; (JP).
KISHI, Yoshiro; (JP).
YAHARA, Ichiro; (JP)
Agent: SHIMIZU, Hatsushi; Kantetsu Tsukuba Bldg. 6F 1-1-1, Oroshi-machi Tsuchiura-shi, Ibaraki 3000847 (JP)
Priority Data:
2004-010971 19.01.2004 JP
(JA) 炎症性サイトカイン抑制剤
Abstract: front page image
(EN)Paying attention to the relationship between inflammatory diseases and cytokines, attempts are made to search for a functional antibody endogenously inhibiting cytokines. A mouse is immunized with a human peripheral monocyte fraction and cytokine inhibitory effects of the thus obtained antibodies are examined. As a result, it is confirmed that, among these antibodies, an antibody #33 inhibits the production of a large number of typical inflammatory cytokines. At the same time, the IL-10 production promoting effect of the antibody #33 is examined. As a result, it is found out that the antibody #33 shows an effect of facilitating the production of IL-10 but has no activity of inducing excessive IL-10 production. It is further clarified that the antigen of this hopeful antibody is CD61. Therefore, it is expected that the application of the anti-CD61 antibody to the treatment of inflammatory diseases would enable the provision of a drug having a reliable efficacy and a high safety.
(FR)L'invention se rapporte à la relation entre les maladies inflammatoires et les cytokines, et à la recherche d'un anticorps fonctionnel permettant le blocage endogène des cytokines. A cette fin on a immunisé une souris avec une fraction de monocyte du sang périphérique humain, et on a examiné les effets inhibiteurs des anticorps résultants sur les cytokines. Cette étude a permis de confirmer que parmi ces anticorps, l'anticorps no. 33 bloque la production d'un grand nombre de cytokines inflammatoires caractéristiques. Simultanément l'effet promoteur de cet anticorps no. 33 sur la production de l'IL-10 a été analysé, ce qui a permis de constater que l'anticorps no 33 exerce un effet facilitant sur la production d'IL-10 mais ne provoque pas une production excessive de cette dernière. Il a en outre été découvert que l'antigène de cet anticorps prometteur est CD61. Cet anticorps anti-CD61 présente par conséquent une application potentielle pour le traitement des maladies inflammatoires, et pour la préparation d'un médicament présentant une efficacité assurée, et des risques minimes.
(JA) 炎症性疾患とサイトカインの関係に注目し、内在的にサイトカインを制御する機能抗体を探索した。ヒト末梢血単核球画分でマウスを免疫し、得られた抗体のサイトカイン制御効果について検討したところ、そのうちの一つである#33抗体が多くの代表的炎症性サイトカイン産生を抑制することを確認した。同時に、#33抗体のIL-10産生促進効果を検討したところ、#33抗体はIL-10産生を早める効果はあるが、過剰なIL-10産生を誘導する活性はないことがわかった。この有望な抗体の抗原を確認したところ、CD61であることがわかった。したがって、抗CD61抗体を炎症性疾患治療に応用した場合には、確実な有効性と高い安全性を兼ね備えた医薬品になると思われる。
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: Japanese (JA)
Filing Language: Japanese (JA)